Cipla launches ‘Covi-G’, a rapid antibody test kit for COVID-19
Global pharmaceutical company, Cipla Limited announced that it has signed a licensing agreement with Multi G, a Belgium-based company for distribution of its Rapid Antibody test kit for COVID-19.
The distribution of Covi-G will be done in Europe and across most of the emerging markets. As a part of the agreement, Cipla will take the responsibility of distribution of the COVID-19 rapid antibody kit manufactured by MultiG which will be marketed under the brandname of ‘Covi-G’.
To read the entire article, you must be a DSIJ magazine subscriber.